Rationale for CD40 pathway blockade in autoimmune rheumatic disorders

Valentina Pucino; David Gardner; Benjamin Fisher

doi:10.1016/S2665-9913(20)30038-2

Rationale for CD40 pathway blockade in autoimmune rheumatic disorders

Valentina Pucino, David Gardner, Benjamin Fisher

Inflammation and Ageing

Research output: Contribution to journal › Review article › peer-review

867 Downloads (Pure)

Abstract

CD40 and its ligand CD40L (CD154) belong to the tumor necrosis factor receptor superfamily and are expressed by a variety of immune and non-immune cells. CD40L plays a central role in co-stimulation and regulation of the immune response via activation of cells expressing CD40. Imbalance of the CD40–CD40L co-stimulatory pathway has been reported in many autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome, thus supporting its role in the breach of immune tolerance that is typical of these diseases. Targeting CD40–CD40L signalling might represent a novel therapeutic option for several autoimmune disorders.

Original language	English
Pages (from-to)	e292-e301
Journal	The Lancet Rheumatology
Volume	2
Issue number	5
Early online date	30 Apr 2020
DOIs	https://doi.org/10.1016/S2665-9913(20)30038-2
Publication status	Published - May 2020

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.1016/S2665-9913(20)30038-2Licence: None: All rights reserved

Pucino_et_al_Rationale_for_CD40_pathway_blockade_The_Lancet_Rheumatology_2020Accepted author manuscript, 718 KBLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

https://www.sciencedirect.com/science/article/pii/S2665991320300382Licence: None: All rights reserved

Cite this

@article{bf081408476c48f695aff6054a989ec1,

title = "Rationale for CD40 pathway blockade in autoimmune rheumatic disorders",

abstract = "CD40 and its ligand CD40L (CD154) belong to the tumor necrosis factor receptor superfamily and are expressed by a variety of immune and non-immune cells. CD40L plays a central role in co-stimulation and regulation of the immune response via activation of cells expressing CD40. Imbalance of the CD40–CD40L co-stimulatory pathway has been reported in many autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and Sj{\"o}gren's syndrome, thus supporting its role in the breach of immune tolerance that is typical of these diseases. Targeting CD40–CD40L signalling might represent a novel therapeutic option for several autoimmune disorders.",

author = "Valentina Pucino and David Gardner and Benjamin Fisher",

year = "2020",

month = may,

doi = "10.1016/S2665-9913(20)30038-2",

language = "English",

volume = "2",

pages = "e292--e301",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Rationale for CD40 pathway blockade in autoimmune rheumatic disorders

AU - Pucino, Valentina

AU - Gardner, David

AU - Fisher, Benjamin

PY - 2020/5

Y1 - 2020/5

N2 - CD40 and its ligand CD40L (CD154) belong to the tumor necrosis factor receptor superfamily and are expressed by a variety of immune and non-immune cells. CD40L plays a central role in co-stimulation and regulation of the immune response via activation of cells expressing CD40. Imbalance of the CD40–CD40L co-stimulatory pathway has been reported in many autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome, thus supporting its role in the breach of immune tolerance that is typical of these diseases. Targeting CD40–CD40L signalling might represent a novel therapeutic option for several autoimmune disorders.

AB - CD40 and its ligand CD40L (CD154) belong to the tumor necrosis factor receptor superfamily and are expressed by a variety of immune and non-immune cells. CD40L plays a central role in co-stimulation and regulation of the immune response via activation of cells expressing CD40. Imbalance of the CD40–CD40L co-stimulatory pathway has been reported in many autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome, thus supporting its role in the breach of immune tolerance that is typical of these diseases. Targeting CD40–CD40L signalling might represent a novel therapeutic option for several autoimmune disorders.

UR - http://www.scopus.com/inward/record.url?scp=85083879821&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(20)30038-2

DO - 10.1016/S2665-9913(20)30038-2

M3 - Review article

SN - 2665-9913

VL - 2

SP - e292-e301

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 5

ER -

Rationale for CD40 pathway blockade in autoimmune rheumatic disorders

Abstract

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this